Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Experience with type 1 Boston KPro

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Surgical Cornea

Session Date/Time: Saturday 10/09/2016 | 15:00-16:30

Paper Time: 16:20

Venue: Poster Village: Pod 3

First Author: : T.Lansini BRAZIL

Co Author(s): :    S. Kwitko   D. Rushel Marinho   A. Prestes Stolz        

Abstract Details

Purpose:

The purpose of our study was to evaluate the outcomes and complications of the Boston KPro in a retrospective case series from a single center, who all received similar surgical treatment and KPro technology.

Setting:

Hospital de Clinicas de Porto Alegre

Methods:

A retrospective case series was performed on all patients undergoing Boston KPro implantation at Hospital de Clinicas de Porto Alegre performed between September 2005 and August 2014. A minimum follow-up of 6 months was required. Using a computerized patient database, 35 eyes of 29 patients were identified that met these criteria. Boston KPro implantation was performed via the standard technique.

Results:

Thirty-five eyes of 29 patients were studied. No patients were lost to follow-up before 6 months. Mean follow up was 56.13 months (6 to 96 months). The Boston KPro was implanted in 20 right eyes and 15 left eyes. There were 13 females and 22 males. There were no significant differences on eyes involved or sex. Mean patient age at the time of KPro implantation was 47 years-old (range, 13 to 81 years-old SD=48,08) for all patients;

Conclusions:

In conclusion, our cases series suggests that the KPro is a promising alternative for high risk PKP patients, and seems to be a viable option specially in cases of alkali burn and multiple previous PKP failures. One main advantage of the Boston KPro is no need of systemic immunosuppression. However, vision-threatening complications continue to be a major problem of this procedure, specially in a long-term follow-up.

Financial Disclosure:

NONE

Back to previous